Business Context and Reporting Period
This Form 8-K Current Report was filed by Coherus BioSciences, Inc. on September 9, 2022, regarding events occurring on September 7, 2022. The filing addresses a change in executive leadership within the finance department.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Appointment: Bryan McMichael was appointed as Senior Vice President, Accounting, Corporate Controller, and Principal Accounting Officer, effective September 7, 2022.
- Departure from Role: McDavid Stilwell ceased serving as Principal Accounting Officer effective September 7, 2022, but continues as Chief Financial Officer and Principal Financial Officer.
- Reason for Change: The transition is described as a planned shift of responsibilities and is explicitly not due to any disagreement regarding operations, financial statements, internal controls, or accounting practices.
Guidance, Outlook, and Compensation
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Regarding compensation for the new appointment:
- Stock Options: Mr. McMichael was granted an option award for 15,000 shares of common stock, vesting monthly over four years.
- Indemnification: The Company will enter into a standard indemnification agreement with Mr. McMichael.
Investor Verification Checklist
- Verify the effective date of the Principal Accounting Officer transition (September 7, 2022).
- Confirm that the change in title for McDavid Stilwell was not related to any accounting disputes or disagreements.
- Review the vesting schedule and terms of the 15,000-share stock option grant to Bryan McMichael.
- Check for any subsequent filings regarding the resignation or departure of McDavid Stilwell from the company entirely.